Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FucoVital is a patented, all‑natural fucoxanthin‑rich oleoresin dietary ingredient derived from the microalga Phaeodactylum tricornutum and standardized to about 3% fucoxanthin along with omega‑3 fatty acids such as EPA and other beneficial lipids.[2][8][10][1] Developed by Algatech (Algatechnologies, part of Solabia), it is positioned for liver health and metabolic support, with preclinical and early clinical data indicating reductions in blood triglyceride levels and inhibition of fat accumulation in liver cells, effects that are partly attributed to inhibition of pancreatic lipase and modulation of lipid metabolism relevant to metabolic syndrome and non‑alcoholic fatty liver disease.[4][10][16][19] FucoVital is the first microalgae‑derived fucoxanthin composition to receive FDA New Dietary Ingredient Notification for use in dietary supplements, is cultivated in a closed, sustainable photobioreactor system, and is marketed as a premium nutraceutical ingredient for incorporation into oral formulations such as capsules for liver and cardiometabolic health applications.[2][5][8][1][13]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FucoVital.